Is Big Pharma really helping us heal—or just keeping us dependent?

In this episode, I speak with Cass, a former strategist in global pharma and biotech, who’s now mentoring leadership teams across the industry. She brings a rare, honest perspective from the inside—one that challenged how I think about conventional medicine, drug pricing, and rare disease treatment.

We cover:

• What’s really driving decisions inside pharmaceutical companies
• Why prescription costs are so high (and where the money goes)
• The challenge of developing drugs for rare diseases like MEN1
• What patients often don’t see when it comes to profit vs care
• Why the alternative vs conventional medicine debate is flawed

This episode blends strategic expertise with a deep belief in human potential, especially powerful if you’re navigating rare disease as a patient and trying to make sense of the system.

About Our Guest

Cass began her career in pharma sales and strategy before moving into global consulting. Today, she coaches leadership teams in £10M–£100M pharmaceutical and biotech companies, helping to drive purpose-led growth while improving wellbeing and retention. She’s also a yoga teacher and firm believer in the power of self-determination and conscious health.

More about Cass here

Are you sure MEN1 can’t be influenced? Join my community to learn how better quality conversation and radical self-responsibility has kept me away from symptoms, surgery & meditation. Click here

Disclaimer
I share my personal experience as a MEN1 patient. Nothing in this episode, including the opinions of my guests, is intended as medical or holistic advice. Please consult a qualified professional before making changes to your care.